Videos and Webcasts

EC APA Update (Webcast, May 16, 2022 - 3pm CEST)

Q1 2022 Financial Results and Corporate Updates (Webcast, May 5, 2022)

First look at Valneva's new Hans Wigzell Vaccine Facility in Sweden

2021 Financial Results and Corporate Updates (Webcast, March 24, 2022)

Valneva's CEO Thomas Lingelbach comments on Valneva's 2021 achievements and its focus for 2021

Valneva's Chief Medical Officer Juan Carlos Jaramillo, MD, comments on vaccine development at Valneva

Valneva's Inactivated COVID-19 Vaccine Candidate VLA2001

Valneva Reports Positive Topline Phase 3 Results for COVID-19 Vaccine Candidate VLA2001 (Webcast, October 18, 2021)

Valneva Presentation at the H.C. Wainwright BIOCONNECT 2022 Conference (January 10, 2022)

Interview with Franck Grimaud, President & Chief Business Officer: "Toutes les choses se mettent en place". Perspectives de la biotech après plusieurs annonces sur ses activités

Valneva H1 2021 Financial Results (Webcast, August 10, 2021)

2021 Combined General Meeting (Webcast - Audio in French) - June 23, 2021

Valneva Q1 2021 Financial Results (Webcast May 20, 2021)

Valneva - Now on Nasdaq

Valneva's COVID-19 Vaccine Candidate: An Inside Look at Fill-and-Finish Operations in Sweden

Valneva's COVID-19 Vaccine Candidate: An Inside Look at Manufacturing in Scotland

Valneva FY 2020 Unaudited Results (Webcast on February 25, 2021 at 3 p.m. CET)

Extraordinary General Meeting 2020, December 22, 2020 at 2:00 p.m. CET

Valneva Stands with Science

Nantes : un laboratoire progresse dans la recherche d'un vaccin contre la maladie de Lyme (in French)

Annual General Meeting, June 17, 2020 (Webcast - Audio in French)